HC Wainwright reiterates Buy on Celldex Therapeutics; $64 target
HC Wainwright & Co. maintained a Buy rating on Celldex Therapeutics and kept its $64.00 price target. The target implies 68.9% upside from the Sep 21 close of $37.89.
HC Wainwright & Co. maintained a Buy rating on Celldex Therapeutics and kept its $64.00 price target. The target implies 68.9% upside from the Sep 21 close of $37.89.